Compare LyondellBasell Industries NV (LYB) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? LyondellBasell Industries NV trades at $61.63 (market cap $19.76B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: LyondellBasell Industries NV is far larger — about 20.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and LyondellBasell Industries NV pays a 4.51% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold LyondellBasell Industries NV for 88 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LYB | MRVI | |
|---|---|---|
Market Cap | $19.76B | $977.37M |
Volume | 2,519,506 | 2,742,564 |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $9.00 |
52-Week Low | $42.28 | $2.83 |
Typical Hold Time | 88 Days | 0 Days |
Enterprise Value | $31.35B | $1.08B |
Dividend Yield | 4.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYB trades at $60.01, up 1.01% on the day, with a bearish technical signal from moving averages but neutral oscillators. Revenue declined to $30.15B in 2025, with a net loss of $745M, though Q2 2026 EPS beat expectations at $4.30. The company maintains a dividend payout, with a consensus analyst price target of $68.56. Cash flow from operations improved to $2.26B in 2025, but debt-to-asset ratio rose to 38.18%.
Outlook is mixed: analyst consensus is evenly split between Buy and Hold, with potential upside to the price target, but risks include declining revenue, negative profit margins, and high debt. Recent news highlights dividend sustainability concerns in the chemical sector, though some analysts see earnings recovery potential.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
